Key Points
- Aditxt major shareholder Financial Lp Hrt sold 735,462 shares on June 5 for about $44,127.72, cutting its stake by 59.27% to 505,302 shares.
- The same shareholder also bought 843,622 shares the day before, highlighting heavy insider trading activity around the stock in recent weeks.
- ADTX shares were trading near $0.05, with the company showing a tiny market cap and weak fundamentals; analysts currently rate the stock a Sell.
Aditxt, Inc. (NASDAQ:ADTX - Get Free Report) major shareholder Financial Lp Hrt sold 735,462 shares of the stock in a transaction on Friday, June 5th. The stock was sold at an average price of $0.06, for a total value of $44,127.72. Following the sale, the insider directly owned 505,302 shares in the company, valued at approximately $30,318.12. This trade represents a 59.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Major shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.
Financial Lp Hrt also recently made the following trade(s):
- On Thursday, June 4th, Financial Lp Hrt purchased 843,622 shares of Aditxt stock. The stock was bought at an average cost of $0.08 per share, with a total value of $67,489.76.
- On Friday, April 24th, Financial Lp Hrt sold 1,089 shares of Aditxt stock. The shares were sold at an average price of $7.56, for a total value of $8,232.84.
- On Thursday, April 23rd, Financial Lp Hrt sold 141 shares of Aditxt stock. The stock was sold at an average price of $7.83, for a total transaction of $1,104.03.
- On Tuesday, April 21st, Financial Lp Hrt acquired 2,700 shares of Aditxt stock. The shares were purchased at an average price of $8.91 per share, for a total transaction of $24,057.00.
- On Wednesday, April 22nd, Financial Lp Hrt sold 443 shares of Aditxt stock. The shares were sold at an average price of $8.10, for a total transaction of $3,588.30.
Aditxt Trading Down 19.6%
Shares of NASDAQ:ADTX opened at $0.05 on Tuesday. The firm has a 50 day moving average of $7.33 and a 200-day moving average of $164.13. Aditxt, Inc. has a 12 month low of $0.05 and a 12 month high of $53,451.08. The stock has a market capitalization of $40,918.00, a PE ratio of 0.00 and a beta of 0.84.
Aditxt (NASDAQ:ADTX - Get Free Report) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $315,563.31 earnings per share (EPS) for the quarter. Aditxt had a negative net margin of 360,152.50% and a negative return on equity of 374.60%.
Analysts Set New Price Targets
Several equities analysts have recently issued reports on ADTX shares. Wall Street Zen upgraded Aditxt to a "sell" rating in a research note on Saturday, May 23rd. Weiss Ratings restated a "sell (e+)" rating on shares of Aditxt in a research report on Monday, April 20th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Aditxt currently has an average rating of "Sell".
View Our Latest Research Report on ADTX
About Aditxt
(
Get Free Report)
Aditxt, Inc is a clinical-stage biotechnology company focused on the development and commercialization of natural antimicrobial peptides and microbiome-based detection technologies. Leveraging proprietary peptide libraries, the company aims to provide novel solutions for infection prevention and control across healthcare, food safety, animal health and agricultural markets. Aditxt's approach centers on harnessing peptides that can disrupt microbial cell membranes without promoting resistance, addressing a growing need for alternatives to traditional antibiotics and chemical disinfectants.
The company's product offerings include contract-based microbial detection and identification services, designed to help hospitals, food processors and other regulated industries monitor contamination levels and validate hygiene protocols.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
